Drug intelligence / Profile preview

SMT 14400

Development stage: Preclinical
Lead developer: Summit Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SMT 14400 is an orally available, second-generation imino sugar small molecule being developed as an immunomodulatory therapy with potential applications in infectious diseases, oncology, and allergy. It originates from Summit’s proprietary imino sugar library and is designed to modulate immune responses and host–pathogen interactions, with development focused on bio-defence–related infectious diseases such as anthrax, Ebola, HIV, and influenza, while Summit also pursues its use in cancer and allergic indications.[1][4][17][15]

Beyond the preview

Go deeper on SMT 14400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMT 14400.

Explore the full profile